The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Abstract
Purpose: To describe survival in previously treated patients with metastatic renal cell carcinoma (RCC) who are candidates for clinical trials of new agents as second-line therapy. Patients and Methods: The relationship between pretreatment clinical features and survival was studied in 251 patients with advanced RCC treated during 29 consecutive clinical trials between 1975 and 2002. Clinical features were first examined in univariate analyses, and then a stepwise modeling approach based on Cox regression was used to form a multivariate model. Results: Median survival for the 251 patients was 10.2 months and differed according to year of treatment, with patients treated after 1990 showing longer survival. In this group, the median overall survival time was 12.7 months. Because the purpose of this analysis was to establish prognostic factors for present-day clinical trial design, prognostic factor analysis was performed on these patients. Pretreatment features associated with a shorter survival in the multivariate analysis were low Karnofsky performance status, low hemoglobin level, and high corrected serum calcium. These were used as risk factors to categorize patients into three different groups. The median time to death in patients with zero risk factors was 22 months. The median survival in patients with one of these prognostic factors was 11.9 months. Patients with two or three risk factors had a median survival of 5.4 months. Conclusion: Treatment with novel agents during a clinical trial is indicated for patients with metastatic RCC after progression to cytokine treatment. Three prognostic factors for predicting survival were used to categorize patients into risk groups. These risk categories can be used in clinical trial design and interpretation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Motzer, R. J., Bander, N. H., & Nanus, D. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351207 · Cited by 2,219
Self-citationSurvival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Self-citationMotzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Self-citationChilds, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E. J., Tisdale, J., Dunbar, C., Linehan, W. M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009143431101 · Cited by 998
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
MOTZER, R. J., & RUSSO, P. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67889-5 · Cited by 603
Self-citation(1999) · The Lancet · doi:10.1016/s0140-6736(98)03544-2 · Cited by 601
A bootstrap resampling procedure for model building: Application to the cox regression model
Sauerbrei, W., & Schumacher, M. (1992) · Statistics in Medicine · doi:10.1002/sim.4780111607 · Cited by 600
Motzer, R. J., Bacik, J., Mariani, T., Russo, P., Mazumdar, M., & Reuter, V. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.123 · Cited by 496
Self-citationPyrhönen, S., Salminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T., Juusela, H., Rintala, E., Hietanen, P., & Kellokumpu-Lehtinen, P.-L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2859 · Cited by 441
Négrier, S., Escudier, B., Gomez, F., Douillard, J.-Y., Ravaud, A., Chevreau, C., Buclon, M., Pérol, D., & Lasset, C. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf257 · Cited by 343
Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M. M., Pyle, L., Johnston, S. R. D., Ahern, R., Smith, I. E., & Gore, M. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1004 · Cited by 338
RENAL CELL CARCINOMA: MANAGEMENT OF ADVANCED DISEASE
FIGLIN, R. A. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61897-4 · Cited by 266
Motzer, R. J., Murphy, B. A., Bacik, J., Schwartz, L. H., Nanus, D. M., Mariani, T., Loehrer, P., Wilding, G., Fairclough, D. L., Cella, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2972 · Cited by 264
Self-citationMotzer, R. J., Rakhit, A. K., Schwartz, L. H., Olencki, T. E., Malone, T., Sandstrom, K., Nadeau, R., Parmar, H. R., & Bukowski, R. M. (1998) · PubMed · Cited by 251
Self-citationVogelzang, N. J., & Stadler, W. M. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01041-1 · Cited by 222
Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Berg, W. J., Ginsberg, M. S., Russo, P., Vuky, J., Yu, R., Bacik, J., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.302 · Cited by 133
Self-citationPhase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
Motzer, R. J., Lyn, P., Fischer, P., LIANES, P., Ngo, R. L., Cordon‐Cardo, C., & O'Brien, J. P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1958 · Cited by 77
Self-citationMotzer, R. J., Nanus, D. M., O’Moore, P. V., Scher, H. I., Bajorin, D. F., Reuter, V. E., Tong, W. P., Iversen, J., Louison, C., & Albino, A. P. (1992) · PubMed · Cited by 50
Self-citationPhase II trial of topotecan in patients with advanced renal cell carcinoma
Law, T. M., Ilson, D. H., & Motzer, R. J. (1994) · Investigational New Drugs · doi:10.1007/bf00874445 · Cited by 42
Self-citationA Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma
Berg, W. J., Schwartz, L. H., Amsterdam, A., Mazumdar, M., Vlamis, V., Law, T. M., Nanus, D. M., & Motzer, R. J. (1997) · Investigational New Drugs · doi:10.1023/a:1005902022076 · Cited by 32
Self-citationPhase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma
Law, T. M., Mencel, P. J., & Motzer, R. J. (1994) · Investigational New Drugs · doi:10.1007/bf00873048 · Cited by 24
Self-citationPhase II trial of Didemnin B in patients with advanced renal cell carcinoma
Motzer, R. J., Scher, H. I., Bajorin, D. F., et al. (1990) · Investigational New Drugs · doi:10.1007/bf00198598 · Cited by 19
Self-citationPhase II trial of 4ʼepi-adriamycin for advanced hypernephroma
Benedetto, P. W., Ahmed, T., Needles, B. M., Watson, R. C., & Yagoda, A. (1983) · American Journal of Clinical Oncology · doi:10.1097/00000421-198306050-00007 · Cited by 12
Erratum for Volume 21, pg. 3972
(2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.921 · Cited by 12
Cited by
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Self-citationSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Ljungberg, B., Bensalah, K., Canfield, S., Dabestani, S., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T., Marconi, L., Merseburger, A. S., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.005 · Cited by 3,394
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Self-citationRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,251
Metadata
- Authors
- Motzer, R. J., Bacik, J., Schwartz, L. H., Reuter, V., Russo, P., Marion, S., & Mazumdar, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-02-01
- Volume
- 22
- Issue
- 3
- Pages
- 454-463
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106453307
- Cited by
- 793
- References
- 28
- FWCI
- 33.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.